Should You Buy Amphastar Pharmaceuticals Inc (AMPH) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
AMPH is NOT a good buy right now for a beginner long-term investor who wants to enter immediately. The setup is weakened by sharply lower profitability (2025/Q3 EPS and net income down >50% YoY), heavy insider selling recently, and a still-negative technical trend. Options positioning looks bullish (puts relatively scarce), but that alone isn’t enough to outweigh deteriorating fundamentals and lack of near-term catalysts. If you must act now, this is a wait/hold rather than a buy.
Technical Analysis
Pre-market price is ~26.25, trading below the pivot (27.127), which keeps the near-term bias cautious. Momentum is still bearish but may be stabilizing: MACD histogram is negative (-0.166) yet contracting (downtrend losing strength), while RSI(6) at 43.2 is neutral-to-soft (not oversold). Moving averages are converging, suggesting consolidation rather than a clear reversal. Key levels: immediate support S1 ~25.615 (a break risks S2 ~24.68). Resistance sits at pivot 27.127 then R1 ~28.64. Pattern-based forward look provided is unfavorable on a 1-month horizon (-7.66%), implying the current trend is not yet a confident long-term entry.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.